A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency

NCT05676853 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

Arginase I Deficiency
Hyperargininemia

Interventions

DRUG: Pegzilarginase

Sponsor

Aeglea Biotherapeutics